Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283048 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
A Phase 1 study, sponsored by Toni Choueiri, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01283048: Completed Phase 1 study, sponsored by Toni Choueiri, MD.
NCT01283048 is a Phase 1 study that has completed, run by Toni Choueiri, MD. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01283048, a Phase 1 study, has completed, sponsored by Toni Choueiri, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells. In this research study, the investigators are testing the safety to BKM-120 at different dose levels. The investigators will also be studying how well tolerated BKM-120 is, and how effective BKM-120 can be in the treatment of kidney cancer.
Interventions
- DRUG BKM-120 Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
What the finished NCT01283048 record still lists
NCT01283048 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which BKM-120 Bevacizumab is the first listed.
NCT01283048 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01283048 about?
NCT01283048 is a clinical study titled "Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma". BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells. In this research study, the investigators are testing the safety to BKM...
What is the current status of trial NCT01283048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01283048?
The interventions under investigation include: BKM-120 Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01283048?
This trial is sponsored by Toni Choueiri, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01283048's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia